Report cover image

Middle East Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), By Indication (Oncology, Infectious Diseases), By Country, And Segme

Publisher Grand View Research
Published Oct 06, 2025
Length 150 Pages
SKU # GV20574986

Description

Middle East Cell And Gene Therapy CDMO Market Summary

The Middle East cell and gene therapy CDMO market size was estimated at USD 55.68 million in 2024 and is projected to reach USD 184.18 million by 2033, growing at a CAGR of 14.23% from 2025 to 2033. The market is driven due to several factors, including rising investments in advanced therapeutics, increasing prevalence of genetic disorders, increasing government support for biotech innovation, and the growing need for specialized manufacturing services.

The market is primarily driven due to the region’s growing focus on biotechnology innovation and the rising demand for personalize and advanced therapeutic solutions. Governments across the region, mainly the UAE and Saudi Arabia, are actively investing in life sciences and precision medicine as part of their national development visions (Saudi Vision 2030). Thus, these factors have led to the creation of biotech hubs, innovation zones, and public-private partnerships, which are significantly boosting local capabilities in contract development and manufacturing. Moreover, the increasing cases of rare genetic disorders and cancers in the region are also one of the factors that are prompting both local and international biotech firms to outsource complex manufacturing processes to contract development and manufacturing organizations (CDMOs) specializing in gene-modified therapies, viral vector production, and cell engineering.

Furthermore, increasing strategic collaborations between regional healthcare systems and global pharmaceutical and biotech companies are also contributing to market growth. Several companies are tapping into the region's untapped market and are forming alliances with local CDMOs and research institutions to facilitate clinical development, scale-up production, and market entry. Moreover, regional regulatory authorities are making considerable initiatives to streamline approval processes for advanced therapies, establish centralized frameworks for clinical trials, and ensure GMP-compliant manufacturing environments. Thus, these factors are further fueling market growth.

Middle East Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at regional levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East Cell and Gene Therapy CDMO market report based on phase, product, indication, and country.
  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-clinical
  • Clinical
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Gene Therapy
  • Ex-vivo
  • In-vivo
  • Gene-Modified Cell Therapy
  • CAR T-cell therapies
  • CAR-NK cell therapy
  • TCR-T cell therapy
  • Cell Therapy
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • Middle East
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Middle East Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Middle East Cell And Gene Therapy CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Middle East Cell And Gene Therapy CDMO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. Middle East Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Cell And Gene Therapy CDMO Market Phase Movement Analysis
4.3. Middle East Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
4.4. Pre-clinical
4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Clinical
4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Cell And Gene Therapy CDMO Market Product Movement Analysis
5.3. Middle East Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
5.4. Gene Therapy
5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Ex-vivo
5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. In-vivo
5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Gene-Modified Cell Therapy
5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. CAR T-cell therapies
5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. CAR-NK cell therapy
5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.4. TCR-T cell therapy
5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.5. Other
5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Cell Therapy
5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Cell And Gene Therapy CDMO Market Indication Movement Analysis
6.3. Middle East Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Infectious Diseases
6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Neurological disorders
6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Rare Diseases
6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
7.1. Regional Market Dashboard
7.2. Middle East Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. Saudi Arabia
7.4.1. Key Country Dynamics
7.4.2. Competitive Scenario
7.4.3. Regulatory Framework
7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. UAE
7.5.1. Key Country Dynamics
7.5.2. Competitive Scenario
7.5.3. Regulatory Framework
7.5.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Kuwait
7.6.1. Key Country Dynamics
7.6.2. Competitive Scenario
7.6.3. Regulatory Framework
7.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Oman
7.7.1. Key Country Dynamics
7.7.2. Competitive Scenario
7.7.3. Regulatory Framework
7.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Qatar
7.8.1. Key Country Dynamics
7.8.2. Competitive Scenario
7.8.3. Regulatory Framework
7.8.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Middle East Cell And Gene Therapy CDMO Market Position Analysis, 2024
8.3. Company Profiles
8.3.1. Porton Pharma Solutions, Ltd. (Porton Advanced)
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. WuXi AppTec
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Thermo Fisher Scientific, Inc.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Charles River Laboratories
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Lonza
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. AGC Biologics
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Catalent Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Samsung Biologics
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. OmniaBio
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Rentschler Biopharma SE
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us